82 filings
Page 3 of 5
8-K
3rzt9zg a7g2kfy
25 Feb 21
Tricida Announces Fourth Quarter and Full Year 2020 Financial Results
4:19pm
8-K
l7isn5
22 Feb 21
Departure of Directors or Certain Officers
4:40pm
8-K
fozwx7slug 047zfq4
11 Jan 21
Entry into a Material Definitive Agreement
9:13am
8-K
2zknef
11 Jan 21
Regulation FD Disclosure
9:07am
8-K
kvmhcqz1b4a23z
8 Dec 20
Regulation FD Disclosure
4:14pm
8-K
oi02ps8 mh1xrprvx
4 Dec 20
Departure of Directors or Certain Officers
4:12pm
8-K
ehu6uhqpmyst
9 Nov 20
Tricida Announces Third Quarter 2020 Financial Results
4:18pm
8-K
uipbs
29 Oct 20
Cost Associated with Exit or Disposal Activities
7:39am
8-K
pb3d46a44omnp
24 Aug 20
Tricida Receives Complete Response Letter from the FDA for its New Drug Application for Veverimer for the Treatment of Metabolic Acidosis and Slowing of Kidney Disease Progression in Patients with Metabolic Acidosis Associated with CKD
8:41am
8-K
gx66olccnrh8gcrn
5 Aug 20
Tricida Announces Second Quarter 2020 Financial Results
4:11pm
8-K
5ooziw
15 Jul 20
Tricida Provides Regulatory Update on Veverimer
5:10pm
8-K
nj0 h0g2vnk
30 Jun 20
Departure of Directors or Certain Officers
4:14pm
8-K
vi01wwyfj34
16 Jun 20
Amendments to Articles of Incorporation or Bylaws
4:43pm
8-K
wtgg6
22 May 20
Entry into a Material Definitive Agreement
4:57pm
8-K
hern7ab ogxvnc15
20 May 20
Tricida Announces Proposed Offering of $175 Million Convertible Senior Notes Due 2027
6:12am
8-K
y6h10 gfj7jrap7we1
19 May 20
Entry into a Material Definitive Agreement
8:16am
8-K
7ax g2r44q9u0
7 May 20
Tricida Announces First Quarter 2020 Financial Results
4:16pm
8-K
phhpdulcse
15 Apr 20
Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation April 2020
12:00am
8-K
kxpigc1094cm98181cgd
16 Mar 20
Departure of Directors or Certain Officers
4:11pm
8-K
251l92dus6vfqx
28 Feb 20
Departure of Directors or Certain Officers
4:12pm